⌘K
t
| TIDM | HEMO |
| Share Price | GBX 810.00-3.26% |
| Market Cap | £52.05m |
Hemogenyx Pharmaceuticals plc confirmed that its Annual Report and Accounts for the year ended 31 December 2025, the Notice of Annual General Meeting (AGM), and a Form of Proxy were posted to shareholders on 5 June 2026. The AGM is scheduled for 30 June 2026 at 2:00 pm BST at One Heddon Street, London.
| Date | 5 Jun 2026 |
| Time | 07:00:03 |
| Category | AGMs and other meetings |
| ID | 9025G |
5 June 2026
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Posting of Annual Report & Notice of Annual General Meeting
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2025, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and will shortly be available on the Company's website at https://hemogenyx.com/investors/annual-half-year-reports/.
The AGM is to be held on 30 June 2026 at 2.00 pm BST at One Heddon Street, London, W1B 4BD.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
AlbR Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.